Weill Cornell Medicine is internationally recognized as a premier center for research and clinical care of patients with blood cancers and conducts more clinical research studies for these diseases than any of our regional peers. Our Lymphoma Program is widely regarded as a leader in lymphoma research and therapeutic development, having contributed to the FDA-approval of nearly all therapies currently available to people with lymphoma.
Our clinical trial protocols include studies initiated by Weill Cornell Medicine investigators, pharmaceutical trials, and collaborative, multi-institutional studies. As a participant in a clinical trial, a patient may gain access to new research treatments years before they are widely available.
Browse our open lymphoma clinical trials:
Diffuse Large B-Cell Lymphoma
Mantle Cell Lymphoma
Chronic Lymphocytic Leukemia (CLL)